» Articles » PMID: 33194667

Prognostic Prediction Models Based on Clinicopathological Indices in Patients With Resectable Lung Cancer

Overview
Journal Front Oncol
Specialty Oncology
Date 2020 Nov 16
PMID 33194667
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Serum enzymes, blood cytology indices, and pathological features are associated with the prognosis of patients with lung cancer, and we construct prognostic prediction models based on clinicopathological indices in patients with resectable lung cancer. The study includes 420 patients with primary lung cancer who underwent pneumonectomy. Cox proportional hazards regression was conducted to analyze the prognostic values of individual clinicopathological indices. The prediction accuracies of models for overall survival (OS) and progression-free survival (PFS) were estimated through Harrell's concordance indices (C-index) and Brier scores. Nomograms of the prognostic models were plotted for individualized evaluations of death and cancer progression. We find that the prognostic model based on alkaline phosphatase (ALP), lactate dehydrogenase (LDH), age, history of tuberculosis, and pathological stage present exceptional performance for OS prediction [C-index: 0.74 (95% CI, 0.69-0.79) and Brier score: 0.10], and the prognostic model based on ALP, LDH, and platelet distribution width (PDW), age, pathological stage, and histological type presented outstanding performance for PFS prediction [C-index: 0.71 (95% CI, 0.66-0.75) and Brier score: 0.18]. These findings show that the models based on clinicopathological indices might serve as economic and efficient prognostic tools for resectable lung cancer.

Citing Articles

Assessing lung cancer progression and survival with infrared spectroscopy of blood serum.

Kepesidis K, Stoleriu M, Feiler N, Gigou L, Fleischmann F, Aschauer J BMC Med. 2025; 23(1):101.

PMID: 39984973 PMC: 11846347. DOI: 10.1186/s12916-025-03924-3.


Prediction of injury localization in preoperative patients with gastrointestinal perforation: a multiomics model analysis.

Lu P, Luo Y, Ying Z, Zhang J, Tu X, Chen L BMC Gastroenterol. 2024; 24(1):6.

PMID: 38166815 PMC: 10759549. DOI: 10.1186/s12876-023-03092-9.


A Nomogram to Predict Long-Term Survival Outcomes of Patients Who Undergo Pneumonectomy for Non-small Cell Lung Cancer With Stage I-IIIB.

Wu L, Chen W, Liu X, Jiang W, Huang Y, Lin P Front Surg. 2021; 8:604880.

PMID: 33996882 PMC: 8118124. DOI: 10.3389/fsurg.2021.604880.


A Low Albumin-to-Globulin Ratio Predicts a Poor Prognosis in Patients With Metastatic Non-small-cell Lung Cancer.

Lu P, Ma Y, Wei S, Liang X Front Med (Lausanne). 2021; 8:621592.

PMID: 33732716 PMC: 7956965. DOI: 10.3389/fmed.2021.621592.

References
1.
Jochems A, El-Naqa I, Kessler M, Mayo C, Jolly S, Matuszak M . A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy. Acta Oncol. 2017; 57(2):226-230. PMC: 6108087. DOI: 10.1080/0284186X.2017.1385842. View

2.
Wu B, Wei S, Tian J, Song X, Hu P, Cui Y . [Comparison of the Survival Time in the Non-small Cell Lung Cancer Patients with Different Organ Metastasis]. Zhongguo Fei Ai Za Zhi. 2019; 22(2):105-110. PMC: 6397941. DOI: 10.3779/j.issn.1009-3419.2019.02.05. View

3.
Greene F, Sobin L . The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin. 2008; 58(3):180-90. DOI: 10.3322/CA.2008.0001. View

4.
Zhang Y, Chen B, Wang L, Wang R, Yang X . Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis. Medicine (Baltimore). 2019; 98(3):e13788. PMC: 6370019. DOI: 10.1097/MD.0000000000013788. View

5.
Pilotto S, Sperduti I, Leuzzi G, Chiappetta M, Mucilli F, Ratto G . Prognostic Model for Resected Squamous Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment. J Thorac Oncol. 2017; 13(4):568-575. DOI: 10.1016/j.jtho.2017.12.003. View